MYC-amplified and Myc-overexpressing cell lines both showed relatively higher sensitivity to BKM-120, indicating that patients with a MYC-amplified tumor may do well with such treatment despite previous reports of MYC amplification in a HMEC model of acquired resistance to BEZ235; this disparity may reflect the fact that BEZ235 exerts it anticancer effects primarily through ATR inhibition [51]. Here, ATR is linked to neoplasm.